血必净注射液治疗慢性阻塞性肺疾病合并社区获得性肺炎的临床观察

Clinical Observation of Xuebijing Injection in the Treatment of Chronic Obstructive Pulmonary Disease Complicated with Community-acquired Pneumonia

目的:探讨血必净注射液治疗慢性阻塞性肺疾病合并社区获得性肺炎的临床疗效及安全性。方法:选取我院2013年2月-2015年1月收治的慢性阻塞性肺疾病合并社区获得性肺炎患者88例,按随机数字表法分为对照组和观察组,各44例。对照组患者给予抗感染、化痰、补液、营养支持等常规治疗,观察组患者在对照组基础上加用血必净注射液50 m L加入0.9%氯化钠注射液100 m L中,ivgtt,滴注时间30~40 min,bid,连续治疗10 d。观察两组患者临床疗效、抗菌药物使用时间及治疗前后肺功能指标[第1秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC及肺活量(VC)],并记录不良反应发生情况。结果:观察组患者总有效率为88.64%,显著高于对照组的70.45%,差异有统计学意义(P<0.05)。观察组患者抗菌药物使用时间明显短于对照组,差异有统计学意义(P<0.05)。两组患者治疗前FEV1、FVC、FEV1/FVC、VC水平比较,差异均无统计学意义(P>0.05);治疗后,两组患者FEV1、VC显著改善,且观察组显著优于对照组,差异均有统计学意义(P<0.05),而FVC、FEV1/FVC治疗前后及组间比较,差异均无统计学意义(P>0.05)。两组患者均未见明显不良反应发生。结论:血必净注射液治疗慢性阻塞性肺疾病合并社区获得性肺炎疗效显著,能明显缩短抗菌药物使用时间,改善患者肺功能,且安全性较好。

OBJECTIVE： To investigate clinical efficacy and safety of Xuebijing injection in the treatment of chronic ob- structive pulmonary disease （COPD） complicated with community-acquired pneumonia （CAP）. METHODS： A total of 88 COPD patients with CAP selected from our hospital during Feb. 2013-Jan. 2015 were divided into control group and observa- tion group according to random number table, with 44 cases in each group. Control group received routine treatment as an- ti-infection, reducing phlegm, fluid replacement, nutritional support, etc. Based on control group, observation group was ad- ditionally given Xuebijing injection 50 mL added into 0.9% Sodium chloride injection 100 mL, ivgtt, for 30-40 min, bid, for consecutive 10 d. Clinical efficacy, application time of antibiotics, pulmonary function indexes [FEV1, FVC, FEV1/ FVC, VC] were observed in 2 groups. The occurrence of ADR was recorded. RESULTS： Total response rate of observation group was 88.64%, which was significantly higher than 70.45% of control group, with statistical significance （P〈0.05）. The application time of antibiotics in observation group was significantly shorter than control group, with statistical significance （P〈0.05）. There was no statistical significance in FEV1, FVC, FEV1/FVC, VC between 2 groups before treatment （P〉 0.05）. After treatment, FEV1 and VC of 2 groups were improved significantly, and the observation group was better than the control group, with statistical significance （P〈0.05）. There was no statistical significance in FVC, FEV1/EVC before and after treatment and betwean the two groups （P〉0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Xuebijing injection has significant therapeutic efficacy for COPD complicated with CAP and can significantly shorten the use time of antibiotics, improve pulmonary function with good safety.